⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VIR News
Vir Biotechnology, Inc. Common Stock
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
businesswire.com
VIR
Chronic Hepatitis D Market Poised for Significant Growth During the Forecast Period (2025-2034) as Emerging Therapies Drive Optimism | DelveInsight
prnewswire.com
VIR
GILD
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
prnewswire.com
ONCY
CHRS
MRNA
VIR
MRK
TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook 2026-2030 with Focus on US, China, South Korea, Australia, and Europe - ResearchAndMarkets.com
businesswire.com
GILD
MRK
CGEN
VIR
TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines
globenewswire.com
GILD
MRK
ARCX
CGEN
VIR
Vir Biotechnology to Present at the 44 th Annual J.P. Morgan Healthcare Conference
businesswire.com
VIR
Norgine enrichit son portefeuille d'hépatologie et de spécialités grâce à un accord de licence exclusif avec Vir Biotechnology USA - Français USA - English USA - English USA - Deutsch Italia - Italiano USA - español
prnewswire.com
VIR
ALNY
Norgine mejora su cartera de productos de hepatología y especialidades USA - español USA - Deutsch Italia - Italiano USA - English USA - English
prnewswire.com
VIR
ALNY
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology USA - Deutsch USA - English USA - English
prnewswire.com
VIR
ALNY
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology USA - English USA - English
prnewswire.com
VIR
ALNY